Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysis.
| Title: | Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysis. |
|---|---|
| Authors: | Bardhi O; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Daher D; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Patel M; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Seif El-Dahan K; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Rich NE; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Mitta S; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Parikh ND; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Pillai A; Department of Internal Medicine, University of Chicago, Chicago, IL, USA.; Kulik LM; Department of Internal Medicine, Northwestern University, Evanston, IL, USA.; Yang JD; Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Kulkarni AV; Department of Hepatology and Liver Transplantation, AIG Hospitals, Hyderabad, India.; Gopal P; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Singal AG; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. |
| Source: | JHEP reports : innovation in hepatology [JHEP Rep] 2025 Feb 26; Vol. 7 (6), pp. 101368. Date of Electronic Publication: 2025 Feb 26 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101761237 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5559 (Electronic) Linking ISSN: 25895559 NLM ISO Abbreviation: JHEP Rep Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Amsterdam] : Elsevier B.V., [2019]- |
| Abstract: | Background & Aims: Older adults have lower treatment eligibility and worse survival across cancer types; however, the association between age and outcomes in patients with hepatocellular carcinoma (HCC) has not been well characterized.; Methods: We performed a search of the PubMed, Ovid MEDLINE, and EMBASE databases from January 2000 to July 2022 to identify studies reporting tumor stage, curative treatment, and overall survival among patients with HCC, stratified by age. Using the DerSimonian and Laird method for a random-effects model, we calculated pooled risk ratios (RRs) for curative treatment receipt and hazard ratios (HRs) for overall survival among younger and older patients (per age thresholds in each study).; Results: We identified 103 studies (n = 154,152 patients) that reported outcomes in younger vs. older patients with HCC. Younger patients were more likely to undergo curative treatment (RR 1.48, 95% CI 1.24-1.77; I2 = 99%), although few studies reported treatment among those with early-stage HCC. Younger patients had better survival than older patients (HR 0.87, 95% CI 0.83-0.92; I2 = 89%), which was consistent in subgroups using age thresholds of |
| Competing Interests: | AGS has served as a consultant or on advisory boards for Genentech, AstraZeneca, Eisai, Exelixis, Bayer, Boston Scientific, Sirtex, Histosonics, FujiFilm Medical Sciences, Exact Sciences, Roche, Glycotest, Freenome, and GRAIL. NDP has served as a consultant or on advisory boards for Eisai, Exelixis, FujiFilm Medical Sciences, Sirtex, AstraZeneca, and Gilead. NER has served as consultant or on advisory boards for AstraZeneca, Eisai, Exelixis, and Genentech. AP is on the medical advisory board for Genentech, AstraZeneca, and Replimune. JDY provides a consulting service for AstraZeneca, Eisai, Exact Sciences, and FujiFilm Medical Sciences. None of the other authors have any relevant conflicts of interest to disclose. Please refer to the accompanying ICMJE disclosure forms for further details. |
| References: | World J Gastroenterol. 2006 Jan 7;12(1):48-53. (PMID: 16440416); BMJ. 2021 Mar 29;372:n71. (PMID: 33782057); Cancer Epidemiol Biomarkers Prev. 2024 Apr 3;33(4):463-470. (PMID: 38252039); Transplantation. 2014 Jul 15;98(1):94-9. (PMID: 24646768); JHEP Rep. 2023 Sep 13;5(12):100907. (PMID: 38034881); Dig Liver Dis. 2011 Dec;43(12):1001-5. (PMID: 21798829); J Hepatol. 2022 Dec;77(6):1598-1606. (PMID: 36208844); Clin Gastroenterol Hepatol. 2023 Jul;21(8):2135-2149. (PMID: 36813012); PLoS One. 2017 Sep 8;12(9):e0184160. (PMID: 28886106); Gastroenterology. 2023 Nov;165(5):1280-1291. (PMID: 37737817); Clin Gastroenterol Hepatol. 2021 Sep;19(9):1925-1932.e1. (PMID: 32920214); J Hepatol. 2022 Jul;77(1):55-62. (PMID: 35157959); J Hepatol. 2022 Jul;77(1):128-139. (PMID: 35139400); J Korean Med Sci. 2012 Oct;27(10):1147-54. (PMID: 23091310); J Am Coll Surg. 2013 Nov;217(5):896-906. (PMID: 24041557); Clin Gastroenterol Hepatol. 2024 Apr;22(4):760-767.e1. (PMID: 37544418); Pharmaceuticals (Basel). 2021 Mar 08;14(3):. (PMID: 33800217); J Hepatol. 2006 Jan;44(1):158-66. (PMID: 16290309); Transplantation. 2008 Jul 15;86(1):104-7. (PMID: 18622285); Aliment Pharmacol Ther. 2020 Aug;52(4):701-709. (PMID: 32598091); Medicine (Baltimore). 2014 Dec;93(28):e264. (PMID: 25526453); Gut. 2021 Feb;70(2):401-407. (PMID: 32398224); J Gastroenterol Hepatol. 2010 Aug;25(8):1426-34. (PMID: 20659234); Am J Transplant. 2009 Apr;9(4 Pt 2):970-81. (PMID: 19341419); J Geriatr Oncol. 2017 Jul;8(4):277-283. (PMID: 28389117); J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630); BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563); Hepatology. 2020 Nov;72(5):1654-1665. (PMID: 32017165); N Engl J Med. 1996 Mar 14;334(11):693-9. (PMID: 8594428); Crit Rev Oncol Hematol. 2005 Sep;55(3):231-40. (PMID: 15979890); Hepatology. 2023 Dec 1;78(6):1922-1965. (PMID: 37199193); Liver Int. 2017 Aug;37(8):1184-1192. (PMID: 28214386); J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281); Clin Gastroenterol Hepatol. 2023 May;21(5):1281-1292.e10. (PMID: 35933076); Nat Rev Clin Oncol. 2023 Dec;20(12):864-884. (PMID: 37884736); Hepatology. 2024 Jan 1;79(1):107-117. (PMID: 37401857); J Am Geriatr Soc. 2011 Feb;59(2):241-50. (PMID: 21275934); Cancer Med. 2022 Mar;11(5):1310-1323. (PMID: 35118819); Hepatology. 2021 Feb;73(2):713-725. (PMID: 32383272); Oncologist. 2011;16(3):310-8. (PMID: 21349948); Hepatology. 2017 Apr;65(4):1196-1205. (PMID: 27775821); World J Gastrointest Oncol. 2015 Oct 15;7(10):204-20. (PMID: 26483875); ERJ Open Res. 2021 May 24;7(2):. (PMID: 34046489); Clin Gastroenterol Hepatol. 2022 Feb;20(2):e267-e288. (PMID: 33387668) |
| Contributed Indexing: | Keywords: Disparities; Elderly; Liver cancer; Prognosis; Treatment |
| Entry Date(s): | Date Created: 20250619 Latest Revision: 20250620 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12174979 |
| DOI: | 10.1016/j.jhepr.2025.101368 |
| PMID: | 40535553 |
| Database: | MEDLINE |
Journal Article